Skip to content
Search:
Search
Facebook page opens in new window
 
ADCS
Alzheimer's Disease Cooperative Study
ADCSADCS
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • ADCS Intervention Selection Committee
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Lifestyle Interventions
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biorepository
    • ADCS Instruments
    • Preliminary Proposals
    • Combination Therapy Call OPEN
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
      • Donate
  • Steering Committee Members
  • Staff Resources
  • DONATE
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • ADCS Intervention Selection Committee
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Lifestyle Interventions
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biorepository
    • ADCS Instruments
    • Preliminary Proposals
    • Combination Therapy Call OPEN
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
      • Donate
  • Steering Committee Members
  • Staff Resources
  • DONATE

Daily Archives: February 16, 2018

You are here:
  1. Home
  2. 2018
  3. February
  4. 16

Raskin, Peskind NEJM Article on Prazosin for PTSD in Veterans

Research NewsBy ADCS AdminFebruary 16, 2018

What’s next in the Raskind/Peskind Prazosin research? They are directing the ADCS’ Peace AD trial which will test Prazosin, as a treatment for disruptive agitation, in people with moderate to severe Alzheimer’s disease. The trial is launching this spring in over 20 memory and long term care communities in the US.

FDA’s Early AD Draft Guidance for Industry on Drug Development for Treatments in Early Alzheimer’s Disease

Research NewsBy ADCS AdminFebruary 16, 2018
Copyright 2017 Regents of the University of California.
Go to Top